Efficacy and Safety of Photodynamic Therapy for Unresectable Cholangiocarcinoma

NACompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

August 31, 2018

Study Completion Date

August 31, 2018

Conditions
Cholangiocarcinoma
Interventions
DEVICE

PDT

"Patients with unresectable CCA are performed PDT with ERCP after porfimer sodium (chongqing ray high medical instrument co., LTD,Chongqing, China) i.v. at a dose of 2 mg/kg at 48 h.~PDT procedure: for light distribution, flexible cylindrical diffuser probes mounted on 400-mm quartz fibres with an active distal tip length of 2 cm (chongqing ray high medical instrument co., LTD,Chongqing, China) is used. The light source was a diode laser system with a maximum power output of 2 Wand a wavelength of 633.3 nm. The power emitted by the diffuser tip was calibrated to 400 mW/cm before PDT was administered using an integrating sphere power meter. The mean irradiation time was 452 s (range: 400-600 s), using a power density of 300-400 mW/cm and an energy dose of 180-200 J/cm (of diffuser length)."

DEVICE

stent

Patients with unresectable CCA are performed with ERCP, one or several plastic biliary stents (Boston Scientific Corporation, MA,USA) are inserted to ensure adequate decompression and bile drainage.

Trial Locations (1)

31006

Hangzhou First People's Hospital, Hangzhou

All Listed Sponsors
lead

First People's Hospital of Hangzhou

OTHER

NCT02585856 - Efficacy and Safety of Photodynamic Therapy for Unresectable Cholangiocarcinoma | Biotech Hunter | Biotech Hunter